CD58 defines regulatory macrophages within the tumor microenvironment

Area of Science:

• Oncology
• Immunology
• Molecular Biology

Background:

• CD58 is linked to immune suppression and cancer stemness.
• Effective biomarkers for immunotherapy response in cancer are needed.
• Glioma immunotherapy response prediction remains a challenge.

Purpose of the Study:

• To investigate the immune predictive significance of CD58 in glioma patients.
• To assess CD58 as a potential biomarker for glioma immunotherapy.

Main Methods:

• Correlation analysis of CD58 expression with clinicopathologic features in glioma.
• In vivo studies comparing tumor formation of CD58-high vs. CD58-low glioma cells.
• In vitro analysis of CD58-high glioma's effect on macrophage polarization and PD-L1 expression.

Main Results:

• CD58 expression correlates with glioma clinicopathologic characteristics.
• CD58-high glioma cells exhibit accelerated tumor formation in vivo.
• CD58-high glioma promotes M2 macrophage polarization via CXCL5, leading to IL-6-mediated PD-L1 upregulation.

Conclusions:

• CD58 may serve as a prognostic marker for glioma tumorigenic potential.
• CD58 expression influences the tumor microenvironment, impacting immunotherapy targets like PD-L1.
• Assessing CD58 expression is a promising strategy for identifying glioma patients who may benefit from immunotherapy.